RIM
LCTX icon

Regent Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Regent Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,000
Closed -$17K – 191
2020
Q2 		$17K Hold
20,000
– – 0.01% 185
2020
Q1 		$17K Hold
20,000
– – 0.01% 178
2019
Q4 		$18K Hold
20,000
– – 0.01% 208
2019
Q3 		$20K Hold
20,000
– – 0.01% 204
2019
Q2 		$22K Hold
20,000
– – 0.01% 205
2019
Q1 		$26K Hold
20,000
– – 0.01% 206
2018
Q4 		$18K Sell
20,000
-5,718
-22% -$8.76K 0.01% 195
2018
Q3 		$53K Hold
25,718
– – 0.02% 203
2018
Q2 		$46K Hold
25,718
– – 0.02% 199
2018
Q1 		$61K Hold
25,718
– – 0.02% 204
2017
Q4 		$48K Hold
25,718
– – 0.02% 205
2017
Q3 		$64K Hold
25,718
– – 0.02% 207
2017
Q2 		$71K Buy
25,718
+11,430
+80% +$31.9K 0.03% 207
2017
Q1 		$43K Hold
14,288
– – 0.02% 199
2016
Q4 		$45K Buy
14,288
+2,858
+25% +$8.78K 0.02% 181
2016
Q3 		$39K Buy
+11,430
New +$31.6K 0.02% 181

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Regent Investment Management's LCTX Position: Q3 2020 in Review

Regent Investment Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2020, closing a stake of 20,000 shares — an estimated $17K sold.

Regent Investment Management first reported a position in LCTX in Q3 2016 and held it in 16 quarters. The position peaked at $71K in Q2 2017. 75 funds tracked by Wall St. Rank hold LCTX as of Q3 2020.

  • Regent Investment Management reported no remaining Lineage Cell Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Regent Investment Management sold 20,000 Lineage Cell Therapeutics shares in Q3 2020, an estimated $17K.
  • Regent Investment Management first reported a position in Lineage Cell Therapeutics in Q3 2016 and held it in 16 quarters.
  • Regent Investment Management's Lineage Cell Therapeutics position peaked at $71K in Q2 2017.
  • 75 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2020.

Based on Regent Investment Management's 13F filing for Q3 2020, filed 19 Oct 2020.